Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

NCT00464646 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

105

Enrollment

NETWORK

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Epirubicin
DRUG: Cyclophosphamide
DRUG: Docetaxel
DRUG: Trastuzumab
DRUG: Bevacizumab

Sponsor

NSABP Foundation Inc

Collaborators

[object Object]
[object Object]